165 related articles for article (PubMed ID: 15070696)
1. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone.
Strömberg T; Dimberg A; Hammarberg A; Carlson K; Osterborg A; Nilsson K; Jernberg-Wiklund H
Blood; 2004 Apr; 103(8):3138-47. PubMed ID: 15070696
[TBL] [Abstract][Full Text] [Related]
2. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.
Yan H; Frost P; Shi Y; Hoang B; Sharma S; Fisher M; Gera J; Lichtenstein A
Cancer Res; 2006 Feb; 66(4):2305-13. PubMed ID: 16489035
[TBL] [Abstract][Full Text] [Related]
3. Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma.
Gu L; Xie L; Zuo C; Ma Z; Zhang Y; Zhu Y; Gao J
BMC Cancer; 2015 Jul; 15():529. PubMed ID: 26189041
[TBL] [Abstract][Full Text] [Related]
4. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
Shi Y; Yan H; Frost P; Gera J; Lichtenstein A
Mol Cancer Ther; 2005 Oct; 4(10):1533-40. PubMed ID: 16227402
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin.
Decker T; Hipp S; Ringshausen I; Bogner C; Oelsner M; Schneller F; Peschel C
Blood; 2003 Jan; 101(1):278-85. PubMed ID: 12393642
[TBL] [Abstract][Full Text] [Related]
6. Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor alpha [corrected].
Abroun S; Ishikawa H; Tsuyama N; Liu S; Li FJ; Otsuyama K; Zheng X; Obata M; Kawano MM
Blood; 2004 Mar; 103(6):2291-8. PubMed ID: 14592826
[TBL] [Abstract][Full Text] [Related]
7. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
[TBL] [Abstract][Full Text] [Related]
8. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).
Jernberg-Wiklund H; Nilsson K
Adv Cancer Res; 2007; 97():139-65. PubMed ID: 17419944
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis.
Gu L; Zhou C; Liu H; Gao J; Li Q; Mu D; Ma Z
J Exp Clin Cancer Res; 2010 Nov; 29(1):150. PubMed ID: 21083937
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin-mediated mTOR inhibition attenuates survivin and sensitizes glioblastoma cells to radiation therapy.
Anandharaj A; Cinghu S; Park WY
Acta Biochim Biophys Sin (Shanghai); 2011 Apr; 43(4):292-300. PubMed ID: 21367753
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of ribosomal p70S6 kinase activation by granulocyte macrophage colony-stimulating factor in neutrophils: cooperation of a MEK-related, THR421/SER424 kinase and a rapamycin-sensitive, m-TOR-related THR389 kinase.
Lehman JA; Calvo V; Gomez-Cambronero J
J Biol Chem; 2003 Jul; 278(30):28130-8. PubMed ID: 12740386
[TBL] [Abstract][Full Text] [Related]
12. Requirement of ClC-3 in G0/G1 to S Phase Transition Induced by IGF-1 via ERK1/2-Cyclins Cascade in Multiple Myeloma Cells.
Du Y; Tu YS; Tang YB; Huang YY; Zhou FM; Tian T; Li XY
Clin Lab; 2018 Jun; 64(6):929-936. PubMed ID: 29945325
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
Ikezoe T; Nishioka C; Bandobashi K; Yang Y; Kuwayama Y; Adachi Y; Takeuchi T; Koeffler HP; Taguchi H
Leuk Res; 2007 May; 31(5):673-82. PubMed ID: 17007924
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
[TBL] [Abstract][Full Text] [Related]
15. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma.
Baumann P; Schneider L; Mandl-Weber S; Oduncu F; Schmidmaier R
Anticancer Drugs; 2012 Jan; 23(1):131-8. PubMed ID: 21959532
[TBL] [Abstract][Full Text] [Related]
17. Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27.
Decker T; Schneller F; Hipp S; Miething C; Jahn T; Duyster J; Peschel C
Leukemia; 2002 Mar; 16(3):327-34. PubMed ID: 11896535
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis.
Gu L; Gao J; Li Q; Zhu YP; Jia CS; Fu RY; Chen Y; Liao QK; Ma Z
Leukemia; 2008 Nov; 22(11):2091-6. PubMed ID: 18685609
[TBL] [Abstract][Full Text] [Related]
19. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
20. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R
Exp Cell Res; 2009 Feb; 315(3):485-97. PubMed ID: 19071109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
